Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML). In a study involving patients with CML in high-income countries, approximately half the patients who ...
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly ...
Researchers sought to determine whether asciminib would have long-term benefit in patients with newly-diagnosed Philadelphia chromosome-positive chronic phase CML.
CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...
Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...
Key abstracts on chronic myeloid leukemia (CML) treatment from the 2025 American Society of Hematology Annual Meeting and Exposition are reported by Dr Jorge Cortes from the Georgia Cancer Center in ...
FluBu2 and FluMel with and without PTCY: Comparative effectiveness and safety in allogeneic stem transplantation for adults with myeloid malignancies. This is an ASCO Meeting Abstract from the 2025 ...
IMproveMF update: Phase 1/1B trial of imetelstat (IME)+ruxolitinib (RUX) in patients (pts) with intermediate (INT)-1, INT-2, or high-risk (HR) myelofibrosis (MF). This is an ASCO Meeting Abstract from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results